Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

20 mars 2026 07h05 HE | Source: Arch Biopartners

Arch Biopartners Announces St. Michael’s Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide

TORONTO, March 20, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that St. Michael’s Hospital (SMH), part of Unity...
16 janv. 2026 08h15 HE | Source: Arch Biopartners

Arch Biopartners Announces Appointment of Dr. Patrick Vink as Chairman of the Board

TORONTO, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today the appointment of Dr. Patrick Vink as Chairman of the...
06 août 2025 07h25 HE | Source: Arch Biopartners

Arch Biopartners Announces First Patient Successfully Dosed at Toronto General Hospital in Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury

First patient successfully completes dosing at Toronto General HospitalSt. Michael’s Hospital is expected to be the next Canadian clinical site activatedArch is looking for additional clinical sites...